By switaschek, 27 May, 2020 Pharmacologic cardioversion5 + peri-procedural anticoagulation3,4 + rate-control tx: flecainide, dofetilide, propafenone, IV ibutilide or amiodarone;5 amiodarone preferred if ICVD or structural heart dz, per ESC
By switaschek, 27 May, 2020 DC cardiovert + periprocedural anticoagulation.3,4 Repeat/serial attempts3,4 based on sinus rhythm duration, sx, pt preference3,4 +/- rate-control tx
By vgreene, 27 May, 2020 Proposed mechanism: hydrolyzes extracellular DNA, decreasing mucus viscosity
By vgreene, 27 May, 2020 Study considerations: retrospective registry study; propensity score matching analysis to minimize confounders but unmeasured variables still possible; dosing and duration only provided in aggregate, dose-response analysis not done; QT intervals not measu
By vgreene, 27 May, 2020 Hydroxychloroquine or Chloroquine With or Without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis
By vgreene, 27 May, 2020 Adjusted analysis for in-hospital mortality (overall 11.1%), CQ 16.4%, CQ + macrolide 22.2%, HCQ 18%, HCQ + macrolide 23.8%, no tx 9.3%; rate of de novo ventricular arrhythmias CQ 4.3%, CQ + macrolide 6.5%, HCQ 6.1%, HCQ + macrolide 8.1%, no tx 0.3%; all